clinical development track ia: a focus on drug safety dara corrigan & ben martin arnold &...
TRANSCRIPT
![Page 1: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/1.jpg)
CLINICAL DEVELOPMENTTrack IA: A Focus on Drug
Safety
Dara Corrigan & Ben Martin
Arnold & Porter LLP
![Page 2: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/2.jpg)
2
Government Oversight
Part I: Ben Martin
Food & Drug Administration (FDA)
Part II: Dara Corrigan
HHS Office of the Inspector General (OIG)CongressState Attorneys General, Other Agencies
![Page 3: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/3.jpg)
3
Part I: FDA Oversight
What We Will Cover:• Use of Pre-Marketing Clinical Studies in Developing
a Drug’s Safety Profile• Post-Marketing Communication of Information in a
Drug’s Safety Profile• Potential Consequences of Non-Compliance
What We Will NOT Cover:• Post-Marketing Surveillance/Pharmacovigillance
Activities
![Page 4: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/4.jpg)
4
Sources of Authority
Current IND Regulations• 42 C.F.R. pt. 312
FDA Guidance Documents Related to Clinical Studies• http://www.fda.gov/oc/gcp/default.htm
ICH Guidelines Related to Clinical Studies• http://www.ich.org/cache/compo/276-254-1.html
Proposed Revisions to IND Regulations• 68 Fed. Reg. 12,406 (Mar. 14, 2003)
![Page 5: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/5.jpg)
5
Drug Safety: The Big Picture
Intense scrutiny recently on drug safety issues• New players on the scene (addressed in Part II)
Recent attention should not obscure the focus historically given to drug safety issues • In 1980s, three criminal prosecutions (Oraflex, Selacryn, &
Merital) alleging that drug companies withheld or failed to report properly AE information
Still, FDA has made drug safety a renewed priority• Organizational restructuring, proposed revisions to its
regulations, new guidance documents, and other initiatives
![Page 6: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/6.jpg)
6
Developing a Safety Profile
Three sources from which a drug sponsor acquires data used to develop a drug’s safety profile:
Controlled clinical studies (pre- and post-marketing) Post-marketing spontaneous AE reports from ANY source
• Clinical studies, literature, MedWatch, other contacts from physicians/patients, lawsuit depositions
Epidemiological analysis of safety database
Clinical data have limited utility in identifying risks• Average # total participants (investigational and placebo)
(4000) vs. low rate of occurrence of some serious risks (1/1000)
![Page 7: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/7.jpg)
7
Development of Clinical Safety Information
Pre-Clinical Data Investigator’s Brochure
Receipt, Evaluation, & Reporting of AEs Clinical Study Reports
Product Labeling
BOTTOM LINE: Process for developing safety information is extremely complex; companies must have adequate organization (personnel and procedures) in place to perform this function
![Page 8: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/8.jpg)
8
Learning from Experience
Drug A: Majority of study population received short-term dosing; ADE related to extended dosing was not observed in pooled data
Drug B: AEs treated individually as minor ADEs later concluded to be symptoms of more serious syndrome
Drug C: Phenomenon thought to indicate efficacy later discovered to be a safety signal
![Page 9: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/9.jpg)
9
FDA’s Safety-Related Initiatives
“Critical Path” Initiative
“Drug Watch” for Emerging Drug Safety Information
Proposed Revision of AE Reporting Requirements in IND/NDA Regulations
Emphasis on “Risk Management”
![Page 10: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/10.jpg)
10
“Critical Path” Initiative
The “Critical Path” refers to the therapeutic product development process
FDA’s March 2004 Report• Addressed recent slowdown in innovative medical
therapies submitted for approval, despite advances in biomedical research
• Called for modernization of tools to access the safety and effectiveness of potential new products earlier and more accurately
“Critical Path Opportunities List”
![Page 11: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/11.jpg)
11
“Drug Watch” Goal: Greater transparency and quicker access for
physicians and patients to safety information Draft guidance issued Dedicated page on FDA’s website
• FDA will post emerging drug safety information it is evaluating
• Could include data in which causation has not been established
Drug Safety Oversight Board (DSB)• Membership includes representatives from CDER offices,
CBER, CDRH, other HHS and non-HHS agencies• Will designate information to be posted on “Drug Watch”
and track safety issues through resolution
![Page 12: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/12.jpg)
12
Reporting Requirements
Proposed revisions:• Would conform FDA’s reporting requirements to
ICH guidelines • Would adopt terminology codifying the
presumption of a causal relationship between AEs and the drug
• Would expand the number of AE reports subject to expedited reporting
• For post-marketing safety reports, would impose new standard for investigating such reports
![Page 13: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/13.jpg)
13
“Risk Management”
“Risk management is an iterative process of (1) assessing a product’s benefit-risk balance, (2) developing and
implementing tools to minimize its risks while preserving its benefits, (3) evaluating tool effectiveness and reassessing the benefit-risk balance, and (4) making adjustments, as
appropriate, to the risk minimization tools to further improve the benefit-risk balance.”
Two Components: • “Risk Assessment”• “Risk Minimization”
![Page 14: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/14.jpg)
14
Pre-Marketing “Risk Assessment”
“Risk assessment consists of identifying and characterizing the nature, frequency, and severity of the risks associated
with the use of a product.”
No “one size fits all” methodology• Consider safety issues when designing and conducting
“efficacy” clinical studies • Preclinical research, similarity to approved treatments,
known metabolic pathways?• Population size and diversity, effect of dose and duration,
potential unexpected interactions? • Adjust existing studies or design new studies based on
new information
![Page 15: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/15.jpg)
15
“Risk Assessment” (cont.)
Adopt a standardized terminology for all studies• Increase likelihood that data could be pooled by avoiding
mixing “apples with oranges”• Verify coding of investigators• Be consistent and accurate when coding AEs
Follow-up with individuals who withdraw
Analyze data thoroughly and “creatively” for expected and unanticipated safety signals• Play the “devil’s advocate”
![Page 16: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/16.jpg)
16
“Risk Minimization”“The goal of risk minimization is to minimize a product’s risks while
preserving its benefits.”
Prescription requirement, product labeling usually adequate• Consider accepting some “labeling risks” in face of
unknown drug risks
Risk Minimization Action Programs (RiskMAPs)• Drug-specific activity based on: nature and rate of
known risk(s) vs. benefit(s), population most at risk or likely to benefit most, existence and risk(s)/benefit(s) of alternatives, reversibility of AE(s), preventability of AE(s), and probability of benefit(s)
![Page 17: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/17.jpg)
17
RiskMAPs RiskMAP Elements
• Specific goal(s), stated in absolute terms• Specific objective(s) that result in processes or
behaviors likely to achieve goal(s)• Specific tool(s) to obtain objective(s)• Method for evaluating effectiveness of tools
RiskMAP Tools• Should maintain widest access to product with least
burden on health system, while achieving risk minimization goal(s)
• Three basic categories• Targeted Education & Outreach• Reminder Systems• Performance-Linked Access Systems
![Page 18: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/18.jpg)
18
Communication of Safety Profile
Safety claims, like efficacy claims:• Must not be “false or misleading in any particular”• Must be “based on competent and reliable scientific
evidence”
Standard applies to all product labeling and advertising
Oral statements attributable to sponsor must be consistent with product label
![Page 19: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/19.jpg)
19
Consequences of Non-Compliance
Withdrawal of IND/NDA
Product Recall
Product Seizure; Disgorgement of Profits
Criminal Prosecution (company and individuals)• Consent Decree; Fines
Product Liability Litigation
![Page 20: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/20.jpg)
20
Summary of Part I
UNDERSTAND COMPLEXITY OF PROCESS FOR DEVELOPING A DRUG’S SAFETY PROFILE
DESIGN CLINICAL STUDIES WITH SAFETY ISSUES IN MIND
ANALYZE DATA THOROUGHLY FOR SAFETY SIGNALS; EXPECT THE UNEXPECTED
CHARACTERIZE THE SAFETY DATA ACCURATELY
An ounce of prevention may be worth a pound of cure
![Page 21: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/21.jpg)
21
Part II:OIG Oversight & Related
Issues
![Page 22: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/22.jpg)
22
OIG’s Relationship to FDA
Beginning in 2000, after the election of President Bush, OIG did not focus on FDA
Similar to OIG’s relationship with CMS, coordination between OIG and FDA is not a routine practice
OIG has traditionally focused on internal reviews of FDA
![Page 23: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/23.jpg)
23
The 2005 OIG Work Plan
11 FDA-related projects in the work plan
Focus primarily on FDA’s internal processes, e.g., monitoring post-marketing studies, oversight of off-label drug promotion
![Page 24: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/24.jpg)
24
The Guidant CIA
New focus on FDA regulatory requirements
Analogous to OIG’s efforts with respect to drug pricing issues
New fraud theories likely to emerge
![Page 25: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/25.jpg)
25
Congressional Scrutiny of FDA
Sen. Grassley’s focus on drug safety and whistleblowers
Sen. Grassley’s recent requests for information related to Guidant
Close relationship between Sen. Grassley and OIG
![Page 26: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/26.jpg)
26
State Involvement . . . and the Media
Data concerning negative clinical studies
Theory of fraud in failing to tell doctors about negative studies
Violation of New York consumer protection laws Marketing data inconsistent with clinical studies
June 3, 2004
SPITZER SUES A DRUG MAKER, SAYING IT HID NEGATIVE DATA
![Page 27: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/27.jpg)
27
COMPARISON OF POTENTIAL DRUG SAFETY CASES TO THE NEURONTIN PROSECUTION
![Page 28: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/28.jpg)
28
Aggressive Prosecution Neurontin Case
Ghost-written articles, trips, sham “educational” session and grants
Example of the type of case that law enforcement likes—potentially high damages and egregious conduct that could put patients in jeopardy
Law enforcement uses legal theoryto recover money
Very high damageslinked to safety issues
Thomas the Tank Engine
![Page 29: CLINICAL DEVELOPMENT Track IA: A Focus on Drug Safety Dara Corrigan & Ben Martin Arnold & Porter LLP](https://reader035.vdocuments.site/reader035/viewer/2022070404/56649f345503460f94c520fb/html5/thumbnails/29.jpg)
29
Summary of Part II
UNDERSTAND THE OIG/LAW ENFORCEMENT VIEW OF THE PHARMACEUTICAL INDUSTRY
REMEMBER THE SUCCESS OF LAW ENFORCEMENT IN PURSUING THE IMPLIED CERTIFICATION THEORY IN THE DRUG PRICING CASES
DEVELOP A COMPREHENSIVE STRATEGY TO DEAL WITH OIG/LAW ENFORCEMENT/CONGRESS/ STATES/MEDIA